University of Notre Dame Du Lac

Klinikum Der Universitat Munchen

Leibniz-institut Für Naturstoff-forschung Und Infektionsbiologie E.v. -hans-knöll-institut- (hki)

Helmholtz-zentrum Fur Infektionsforschung Gmbh

Sebastian Schieferdecker

Marvin J Miller

Rolf Müller

Andreas Kirschning

Hans-Martin Dahse

Kathrin Mohr

Florian Kloss

Axel Brakhage

Ute Möllmann

Julia Dreisbach

Kamil Philip Wojtas

Michael Wolling

Frank Surup

Konrad Viehrig

The present invention relates to the general field of treatment of infectious diseases of mammals (humans and animals) caused by bacteria, in particular to the treatment of diseases like tuberculosis (TB), Buruli ulcer and leprosy caused by mycobacteria. The invention aims at the generation of a new series of benzothiazinone compounds having the potential to overcome the above mentioned problems. In a preferred embodiment the invention is concerned with compounds of the general formula (I) whereinRrepresents NO,Rrepresents CF,at least one of the substituents Rand Ris OH, SR, NHR, CN, N, a saturated or unsaturated, optionally halogenated, linear or branched aliphatic radical having 1-4 carbon atoms, linear or branched C-Calkoxy, C-Cacyl, and the other of Rand Rmay in addition be hydrogen,Rrepresents a 2-methyl-1,4-dioxa-8-azaspiro[4.5]decan-8-yl or a 4-(cyclo-hexylmethyl)piperazin-1-yl group andRand Rindependently of each other are hydrogen or a C-Calkyl group and/or a pharmaceutically acceptable salt thereof.

Antimicrobial compounds, their use for the treatment of mammalian infections and a new metabolic mechanism

Growing community of inventors

Jena, Germany

Sebastian Schieferdecker